Daijiworld Media Network - Ahmedabad
Ahmedabad, Apr 11: Cadila Pharmaceuticals has launched Ciledge Trio, a fixed-dose combination therapy aimed at delivering sustained blood pressure control with improved tolerability and better patient adherence, particularly in hypertensive patients with underlying heart conditions.
The company said the new product strengthens its focus on advanced cardiovascular care and addresses unmet needs in hypertension management.
Ciledge Trio combines three well-established antihypertensive agents—Cilnidipine (calcium channel blocker), Telmisartan (angiotensin receptor blocker), and Metoprolol (β1 selective blocker)—which work through complementary mechanisms to achieve more consistent and effective blood pressure reduction. Clinical evidence suggests that such combination therapy offers superior long-term control and better cardioprotection, especially in patients with co-existing conditions such as angina, myocardial infarction, and heart failure.
Cadila noted that Cilnidipine is associated with a significantly lower incidence of pedal edema compared to conventional calcium channel blockers, while Telmisartan offers sustained blood pressure control along with added benefits for patients with diabetes and chronic kidney disease. Metoprolol further contributes by improving heart rate control and enhancing overall cardiovascular protection.
The company highlighted that combining all three medicines into a single pill reduces pill burden, which can improve medication adherence and long-term treatment outcomes.
Ciledge Trio is supported by Cadila’s proprietary Tri-tab technology, a triple-layered tablet platform designed to ensure stability, reduce drug interaction issues, and maintain consistent drug release and absorption.
Speaking on the launch, Cadila Pharmaceuticals CMD Dr. Rajiv I. Modi said the therapy is designed to deliver efficacy, safety, and long-term cardiovascular protection, aligning with guideline-based hypertension management.
With this launch, Cadila aims to strengthen its cardiovascular portfolio and contribute to better hypertension control, helping reduce India’s long-term burden of cardiovascular disease.